Trial Profile
Sacubitril-valsartan (Entresto) Versus Standard Anti-hypertensive Therapy in LVAD Patients - A Feasibility Pilot Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2023
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Valsartan
- Indications Hypertension
- Focus Therapeutic Use
- 01 Feb 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 14 Sep 2017 New trial record